Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Paclitaxel and Sorafenib
Drug: Paclitaxel

First Posted Date: 2011-03-22

Last Posted Date: 2017-02-20

Lead Sponsor: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Target Recruit Count: 59

Registration Number: NCT01320111

Locations: 🇩🇪
Germany Multiple Sites All Over Germany Recruiting Multiple Sites, Germany Contact: iOMEDICO AG, Freiburg, Germany

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Phase 4

Completed

Conditions: Carcinoma, Large Cell
Neuroendocrine Tumors

Interventions: Drug: RAD001
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2011-03-17

Last Posted Date: 2016-03-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT01317615

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Phase 2

Completed

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Verrucous Carcinoma of the Larynx

Interventions: Biological: cetuximab
Drug: paclitaxel
Drug: carboplatin
Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2011-03-16

Last Posted Date: 2018-02-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 24

Registration Number: NCT01316757

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Univesity of Rochester Medical Center, Rochester, New York, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Dasatinib
Drug: Trastuzumab
Drug: Paclitaxel

First Posted Date: 2011-03-02

Last Posted Date: 2023-03-30

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 37

Registration Number: NCT01306942

Locations: 🇪🇸
Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain
🇪🇸
Instituto Catalán de Oncología de Barcelona (Hospital Duran i Reynalds), Hospitalet de Llobregat, Barcelona, Spain
🇪🇸
Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

and more 5 locations

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Phase 3

Terminated

Conditions: First Line Metastatic Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Bevacizumab
Drug: Exemestane

First Posted Date: 2011-02-25

Last Posted Date: 2023-09-06

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 117

Registration Number: NCT01303679

Locations: 🇫🇷
BACHELOT, Lyon, France

Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

Phase 2

Completed

Conditions: Angiosarcoma

Interventions: Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2011-02-24

Last Posted Date: 2019-05-30

Lead Sponsor: Centre Oscar Lambret

Target Recruit Count: 70

Registration Number: NCT01303497

Locations: 🇫🇷
Institut Curie, Paris, France
🇫🇷
Institut de Cancérologie de la Loire, SAINT PRIEST en JAREZ, France
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 10 locations

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Cancers

Interventions: Drug: GDC-0980
Drug: bevacizumab
Drug: carboplatin
Drug: cisplatin
Drug: paclitaxel
Drug: pemetrexed

First Posted Date: 2011-02-23

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 75

Registration Number: NCT01301716

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Paclitaxel
Drug: Trastuzumab

First Posted Date: 2011-02-23

Last Posted Date: 2016-12-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 32

Registration Number: NCT01301729

Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer

Phase 1

Conditions: Cervical Adenocarcinoma
Cervical Adenosquamous Carcinoma
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Stage IB Cervical Cancer AJCC v6 and v7
Stage IIA Cervical Cancer AJCC v7
Stage IIB Cervical Cancer AJCC v6 and v7
Stage IIIA Cervical Cancer AJCC v6 and v7
Stage IIIB Cervical Cancer AJCC v6 and v7
Stage IVA Cervical Cancer AJCC v6 and v7

Interventions: Drug: Carboplatin
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Radiation: Internal Radiation Therapy
Drug: Paclitaxel

First Posted Date: 2011-02-14

Last Posted Date: 2019-03-12

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 45

Registration Number: NCT01295502

Locations: 🇺🇸
Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

and more 11 locations

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 1

Completed

Conditions: Ovarian Mucinous Cystadenocarcinoma
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Recurrent Fallopian Tube Carcinoma
Undifferentiated Ovarian Carcinoma
Ovarian Brenner Tumor
Ovarian Serous Cystadenocarcinoma
Malignant Ovarian Mixed Epithelial Tumor
Recurrent Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Drug: TLR8 Agonist VTX-2337
Other: Diagnostic Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Paclitaxel

First Posted Date: 2011-02-11

Last Posted Date: 2014-12-25

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 20

Registration Number: NCT01294293

Locations: 🇺🇸
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy